We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $159K invested in Array Biopharma Inc in 2019 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 316 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 318 → 1 (-317)

100% less funds holding in top 10

Funds holding in top 10: 28 → 0 (-28)

100% less capital invested

Capital invested by funds: $10.5B → $159K (-$10.5B)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 316

Holders
1
Holders Change
-317
Holders Change %
-99.69%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-28
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
316
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$943M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$890M
3
BlackRock
BlackRock
New York
-$824M
4
RG
Redmile Group
California
-$405M
5
FCM
Farallon Capital Management
California
-$394M
Name Holding Trade Value Shares
Change 		Change in
Stake
VEA
226
Virtus ETF Advisers
New York
– -$1.27M -27,357 Closed
Canada Life
227
Canada Life
Manitoba, Canada
– -$1.21M -26,216 Closed
SCM
228
Silvant Capital Management
Georgia
– -$1.18M -25,426 Closed
GCA
229
Gideon Capital Advisors
New York
– -$1.05M -22,781 Closed
Bank of Montreal
230
Bank of Montreal
Ontario, Canada
– -$1.02M -21,968 Closed
LPL Financial
231
LPL Financial
California
– -$939K -20,265 Closed
Adage Capital Partners
232
Adage Capital Partners
Massachusetts
– -$927K -20,000 Closed
MTCM
233
Mint Tower Capital Management
Netherlands
– -$927K -20,000 Closed
AIP
234
Ameritas Investment Partners
Nebraska
– -$879K -18,964 Closed
SAM
235
Shell Asset Management
Netherlands
– -$860K -18,558 Closed
TRSOTSOK
236
Teachers Retirement System of the State of Kentucky
Kentucky
– -$854K -18,432 Closed
SC
237
Slow Capital
California
– -$843K -18,201 Closed
TS
238
Twin Securities
New York
– -$695K -15,000 Closed
HighTower Advisors
239
HighTower Advisors
Illinois
– -$690K -14,866 Closed
PI
240
PEAK6 Investments
Illinois
– -$685K -14,781 Closed
PVAM
241
Pacific View Asset Management
California
– -$666K -14,364 Closed
Zurich Cantonal Bank
242
Zurich Cantonal Bank
Switzerland
– -$659K -14,231 Closed
Capital Fund Management (CFM)
243
Capital Fund Management (CFM)
France
– -$655K -14,133 Closed
GC
244
Grimes & Company
Massachusetts
– -$649K -14,000 Closed
ACA
245
Atlas Capital Advisors
Wyoming
– -$642K -13,866 Closed
TMAM
246
Tokio Marine Asset Management
Japan
– -$635K -13,700 Closed
Simplex Trading
247
Simplex Trading
Illinois
– -$605K -13,080 Closed
Squarepoint
248
Squarepoint
New York
– -$520K -11,232 Closed
SEI Investments
249
SEI Investments
Pennsylvania
– -$520K -11,219 Closed
Mercer Global Advisors
250
Mercer Global Advisors
Colorado
– -$519K -11,192 Closed
8 9
10
11 12

ARRY Hedge Fund Activity: Q3 2019 in Review

1 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2019, worth a combined $159K — down 100% from $10.5B a quarter earlier.

Sellers outnumbered buyers: 316 funds closed out of ARRY and 0 opened new positions — a net loss of 316 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $943M sold.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q3 2019, down from 318 in Q2 2019.
  • Funds reported $159K of Array Biopharma Inc stock for Q3 2019, down 100% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q3 2019 and 316 closed out, a net change of -316 holders.
  • The largest Array Biopharma Inc seller in Q3 2019 was Vanguard Group, an estimated $943M sold.

Based on aggregated 13F filings for Q3 2019.